Aquestive Therapeutics, Inc. (AQST) Net income 2017–2025
Aquestive Therapeutics, Inc. (AQST) annual net income history from SEC filings — each fiscal year as reported, with year-over-year change.
-$83.8MFY2025 · since FY2017: -$8.9M → -$83.8M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$83.8M | -89.8% |
| FY2024 | -$44.1M | -460.8% |
| FY2023 | -$7.9M | +85.5% |
| FY2022 | -$54.4M | +22.9% |
| FY2021 | -$70.5M | -26.5% |
| FY2020 | -$55.8M | +15.8% |
| FY2019 | -$66.2M | -7.9% |
| FY2018 | -$61.4M | -586.3% |
| FY2017 | -$8.9M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More AQST financial trends
AQST RevenueAQST Net marginAQST Gross profitAQST Gross marginAQST Operating incomeAQST Operating marginAQST Operating cash flowAQST Free cash flowAQST Capital expendituresAQST Return on equityAQST Stock buybacksAQST Dividends paidAQST Total assetsAQST Total liabilitiesAQST Shareholders’ equityAQST overview →